Monitor for subsequent announcements of clinical trial supply agreements or revenue from product sales. Without concrete orders or financial guidance, the near-term stock impact is likely muted.
Price Chart
Executive Summary
Optimi Health announced the launch of standardized 1mg and 2mg microdose psilocybin capsules for clinical research, extending its existing 5mg formulation. The products are produced in-house at its GMP facility in Canada. No financial terms, revenue impact, or customer agreements were disclosed.
Key Facts
- Launched two new microdose psilocybin finished drug products at 1mg and 2mg dosages for clinical research organizations.
- Products are naturally derived, GMP-manufactured, and available to qualified authorized researchers.
- Extends existing psilocybin range that includes a 5mg capsule currently prescribed for treatment-resistant depression in Australia.
- All production occurs in-house at Optimi's Health Canada-licensed facility in Princeton, British Columbia.
Financial Impact
No financial impact disclosed; product launch may generate future revenue from clinical research organizations, but no orders or revenue guidance provided.
Risk Factors
- Regulatory uncertainty in psychedelic drug research and commercialization.
- Lack of disclosed revenue or customer commitments; small market cap ($16M) increases volatility.
- Forward-looking statements subject to risks detailed in SEC filings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-271863 |
| Document: d157521d6k.htm | 0001193125-26-271863 |
| Document: 0001193125-26-271863-index-headers.html | 0001193125-26-271863 |
| Document: 0001193125-26-271863-index.html | 0001193125-26-271863 |
| Document: 0001193125-26-271863.txt | 0001193125-26-271863 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $3.36 | awaiting T+5 | — | $3.04 (−9.52%) |
Oct 20, 2026 7d ago | 6-K | $3.36 | awaiting T+5 | — | $3.04 (−9.52%) |
Oct 7, 2026 20d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.04 (−24.75%) |
Oct 5, 2026 21d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.04 (−26.39%) |
Sep 29, 2026 28d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.04 (−36.40%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.04 (−38.71%) |
Sep 22, 2026 5w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.04 (−38.71%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.04 (−37.96%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.04 (−32.44%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.04 (+37.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers